Objective-The proliferation of vascular smooth muscle cells (VSMCs) plays a crucial role in vascular diseases, such as atherosclerosis and restenosis, after percutaneous coronary intervention. Many studies have shown that estrogen inhibits VSMC proliferation in response to vascular injury in the mouse carotid injury model. However, the mechanisms that mediate these effects remain unclear. Here, we investigated the mechanisms by which estrogen inhibits VSMC proliferation. Approach and Results-We established a novel transgenic mouse line, referred to as the disrupting peptide mice, in which rapid estrogen receptor (ER)-mediated signaling is abolished by overexpression of a peptide that prevents the ER from forming a signaling complex necessary for rapid signaling. Carotid artery VSMCs from disrupting peptide mice or littermate wild-type female mice were obtained by the explant method. In VSMCs derived from wild-type mice, estrogen significantly inhibited VSMC proliferation. Phosphorylation levels of Akt and extracellular regulated kinase induced by platelet derived growth factor were significantly inhibited by estrogen pretreatment. Estrogen enhanced complex formation between ERα and protein phosphatase 2A (PP2), and enhanced PP2A activity. The blockade of PP2A activity abolished the estrogen-induced antiproliferative effect on VSMCs. In contrast, none of these effects of estrogen observed in the wild-type VSMCs were observed in VSMCs derived from disrupting peptide mice. These results support that rapid, non-nuclear ER signaling is required for estrogen-induced inhibition of VSMC proliferation, and further that PP2A activation by estrogen mediates estrogen-induced antiproliferative effects. Conclusions-These findings support that PP2A activation via rapid, non-nuclear ER signaling may be a novel target for therapeutic approaches to inhibit VSMC proliferation, which plays a central role in atherosclerosis and restenosis. 
C ardiovascular disease (CVD) is the leading cause of death in the United States. 1 Premenopausal women have a lower incidence of death attributable to CVD than age-matched men in the United States, supporting that the hormone estrogen may have an important protective effect on the vasculature. 2 Although many observational studies have demonstrated that exogenous estrogen therapy is associated with lower primary risk of CVD in postmenopausal women, [3] [4] [5] randomized controlled trials, primarily in older postmenopausal women, have not shown reductions in CVD events and, in some instances, they have demonstrated harm. 6 Numerous animal studies have shown that estrogen significantly protects against the development of atherosclerosis. We and others have repeatedly shown that estrogen inhibits the response to vascular injury in the mouse carotid artery injury model, in which in vivo estrogen treatment dramatically inhibits the proliferation of vascular smooth muscle cells (VSMCs). [7] [8] [9] [10] [11] Taken together with the clinical data, these findings underscore the complexity of the effects of estrogen on the cardiovascular system and highlight its ability to exert both potentially harmful and potentially beneficial effects. This observation strongly supports the need to better understand the molecular mechanisms by which estrogen exerts its cardiovascular effects.
There are 2 different forms of the estrogen receptor (ER), ERα and ERβ. 12 We previously reported that in ERβ knockout (KO) mice, estrogen was still protective against vascular injury, 13 whereas in ERα KO mice, in which ERα is fully deleted, estrogen treatment showed no protective effect on VSMC proliferation after vascular injury, 8 supporting that ERα is necessary for the inhibitory effect of estrogen on VSMC proliferation. Importantly, the molecular mechanisms by which estrogen inhibits VSMC proliferation are unknown.
Estrogen, acting via ERs, activates 2 distinct signaling pathways, the genomic pathway and the rapid, non-nuclear pathway. 2, 14 The genomic pathway has been well studied in which ligand-bound ER translocates to the nucleus and August 2013 transcriptionally regulates gene expression. 2 More recent studies have shown that estrogen also signals through a rapid, non-nuclear signaling pathway that involves activation of specific protein kinases but does not directly involve regulation of gene expression (although cross-talk between these pathways has also now been described). 15, 16 Since their discovery, estrogen-induced protection against vascular injury and the inhibition of VSMC growth have been believed to be attributable to long-term genomic effects, whereas little has been investigated about the role of the rapid, non-nuclear pathway in regulating the response to vascular injury and inhibiting VSMC proliferation, although this pathway is known to be involved in regulating endothelial function and NO release. 12, 17, 18 We previously reported that activation of the non-nuclear pathway by estrogen requires binding between the ER and a scaffold protein, striatin, and that a peptide derived from amino acids 176 to 253 of ERα disrupts the binding between ER and striatin, preventing activation of the non-nuclear signaling pathway, whereas leaving the classical genomic signaling pathway intact. 19 We have established a transgenic mouse line in which this disrupting peptide (disrupting peptide mice [DPM] ) is overexpressed throughout the body. 20 In these DPM, ERα-mediated non-nuclear signaling is disrupted, whereas the canonical genomic pathway is still intact. 20 In this study, we investigated the molecular mechanisms by which estrogen inhibits VSMC proliferation and explored whether non-nuclear ER signaling is involved in the antiproliferative effect of estrogen on VSMCs.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Estrogen-Induced Antiproliferative Effect on VSMCs Requires ERα-Striatin Binding
E2 significantly inhibited the serum-induced proliferation of VSMCs derived from wild-type (WT) mice but not of VSMCs derived from DPM ( Figure 1A ). E2 had no effect on VSMC proliferation derived from ERαKO mice, whereas the E2-induced inhibition was restored by ERα overexpression in VSMCs derived from ERαKO mice ( Figure 1B ). E2 markedly inhibited the increase in mRNA expression of proliferating cell nuclear antigen, a marker of VSMC proliferation, induced by stripped bovine growth serum or platelet derived growth factor (PDGF) in WT VSMCs, but not in DPM VSMCs ( Figure 1C ). E2 significantly activated an estrogen response element-driven luciferase reporter plasmid to a similar degree in VSMCs from both WT mice and DPM ( Figure 1D ), supporting that the genomic ER pathway is still preserved in VSMCs from DPM. These data indicate that E2 directly inhibits WT VSMC proliferation in an ERα-dependent manner, and further that the disruption of ER-striatin binding induced by the disrupting peptide abolishes the antiproliferative effect.
Estrogen Inhibits Kinase Phosphorylation Through Activation of Protein Phosphatase 2A
To examine the mechanisms by which estrogen inhibits VSMC proliferation, we assessed phosphorylation levels of kinases that promote cell growth, including Akt and extracellular regulated kinase (ERK). As expected, PDGF stimulation increased phosphorylation levels of Akt and ERK in WT VSMCs (Figure 2A) . Meanwhile, E2 pretreatment attenuated PDGF-induced phosphorylation of Akt and ERK in a dose-dependent manner ( Figure 2A ). E2-mediated inhibition reached statistical significance at 10 to 100 nmol/L of E2 for phospho-Akt and at 50 to 100 nmol/L of E2 for phospho-ERK. Therefore, we used 100 nmol/L of E2 for further experiments. PDGF stimulation increased phosphorylation levels of Akt, its downstream target glycogen synthase kinase 3 α/β, and ERK, not only in WT VSMCs but also in DPM VSMCs ( Figure 2B ). E2 pretreatment significantly attenuated PDGF-induced kinase phosphorylation in VSMCs from WT mice. In contrast, E2 had no significant effect on PDGF-induced kinase phosphorylation in DPM VSMCs ( Figure 2B ).
To investigate the mechanisms by which E2 inhibits kinase phosphorylation, we examined whether ER in VSMCs interacts with phosphatases. Coimmunoprecipitation experiments revealed that ERα forms a complex with protein phosphatase 2Ac (PP2Ac), but not with either MAPK kinase phosphatase-1 or phosphatase and tensin homolog, all of which are known to dephosphorylate Akt and ERK as their substrate ( Figure I in the online-only Data Supplement). Therefore, we investigated the role of PP2A in estrogen-mediated inhibition of kinase phosphorylation. Immunoprecipitation of PP2Ac showed that E2 clearly increased ERα-PP2Ac complex formation in VSMCs from WT mice, whereas E2-induced ERα-PP2A complex formation was significantly attenuated in DPM VSMCs ( Figure 3A) . Similarly, E2 increased PP2A-striatin complex formation in VSMCs from WT mice but not DPM ( Figure 3A ), suggesting that E2 promotes ERα-PP2Ac complex formation via the scaffold protein striatin. PP2A activity assays revealed that E2 significantly increased PP2A activity in VSMCs from WT mice but had no significant effect in DPM VSMCs ( Figure 3B ). The expression levels of PP2Ac protein were not altered by 30 minutes of E2-treatment ( Figure 3C ), suggesting that E2 increases PP2A activity independently from alteration of PP2A expression levels.
PP2A Activation Is Required for EstrogenInduced Inhibition of Kinase Phosphorylation and Antiproliferative Effect on VSMCs
To determine whether PP2A is involved in E2-mediated inhibition of PDGF-induced Akt and ERK phosphorylation, we next examined whether knock down of PP2A by siRNA attenuated this effect of E2. As shown in Figure 4A , E2 significantly inhibited Akt and ERK phosphorylation in control siRNA-treated WT VSMCs but it no longer inhibited PDGF-induced phosphorylation in WT VSMCs in which PP2A was knocked down. To further investigate the role of PP2A in E2-mediated inhibition of VSMC proliferation, we next examined the effect of PP2A inhibition with a pharmacological PP2A inhibitor, okadaic acid (OA), on the effects of E2 on VSMC proliferation. OA completely inhibited the E2-induced increase in PP2A activity in WT VSMCs (data not shown). The E2-induced antiproliferative effect observed in stripped bovine growth serumstimulated VSMCs from WT mice was completely blocked by OA ( Figure 4B ). Furthermore, OA also significantly blocked the E2-induced antiproliferative effect observed in PDGFstimulated VSMCs from WT mice ( Figure 4C ).
Because the kinases Akt and ERK also mediate apoptosis signaling cascades, we also examined the effects of E2 on apoptosis of VSMCs. Terminal deoxynucleotidyl transferase nick end labeling staining showed that E2 had no effect on apoptosis in VSMCs under quiescent, PDGF-stimulated or serum-stimulated conditions ( Figure II in the online-only Data Supplement).
PP2A Activation Is Required for EstrogenInduced Inhibitory Effect on VSMC Migration
We further examined whether the rapid, non-nuclear signaling pathway is involved in E2-mediated inhibition of PDGF-induced VSMC migration, which also contributes to the development of maladaptive response after vascular injury. In vitro scratch wound assays showed that E2 significantly inhibited cell migration promoted by PDGF in VSMCs derived from WT mice, and that this inhibitory effect of E2 on VSMC migration was abolished in cells treated with OA ( Figure 5A ). In contrast, E2 had no effect on migration in VSMCs derived from ERαKO mice ( Figure 5B ) or in VSMCs derived from DPM ( Figure 5C ).
Discussion
Although we and others have previously shown that estrogen inhibits VSMC proliferation in vitro and in vivo, the molecular mechanisms that mediate this effect remain unknown. Recently, we reported that estrogen-induced protective effects against carotid vascular injury are abolished in DPM in vivo, 20 supporting that the rapid ERα signaling pathway is necessary for the antiproliferative effects of estrogen in vivo. However, the molecular mechanisms that mediate these effects and the specific role of rapid ERα signaling are unknown.
In the current studies, we used cultured VSMCs from WT mice and DPM to explore these issues. We now show that in cultured WT VSMCs, ERα and PP2A can form a complex, that E2-treatment activates PP2A and inhibits phosphorylation of growth promoting kinases, and that the activation of PP2A by estrogen is required for the inhibitory effect of estrogen both on kinase phosphorylation and on VSMC proliferation. Furthermore, we show that these effects are lost in VSMCs derived from the DPM in which the rapid, nonnuclear signaling pathway is disrupted by overexpression of a peptide consisting of amino acids 176 to 253 of ERα, which disrupts formation of the striatin-based signaling complex required for rapid signaling. In addition, E2 significantly inhibited cell migration promoted by PDGF in VSMCs derived from WT mice, but not from DPM, and the inhibitory effect of E2 on VSMC migration was abolished by PP2A inhibition. Taken together, these data support that the rapid, non-nuclear signaling pathway of ER is required for the estrogen-mediated antiproliferative/migratory effects in VSMCs ( Figure 6 ).
PP2A is a major serine/threonine protein phosphatase that has been highly conserved in all eukaryotes.
21 PP2A phosphatase activity is associated with growth inhibition and cell cycle arrest, so that PP2A is known to be a key mediator of tumor growth suppression. [22] [23] [24] Because proliferation of VSMCs is also enhanced in large part by protein kinase-dependent pathways, we explored the role of PP2A activation in E2-mediated inhibition of VSMC proliferation. We previously showed that ER binds to PP2Ac, which is a catalytic subunit of PP2A complex, and that estrogen enhances the interaction between PP2Ac and ERα in endothelial and COS-1 cell lines, respectively. 25 In that study, inhibition of PP2A activity by OA increased ER-mediated transcriptional activity, which is consistent with our current data showing a trend toward increased transcriptional activity of ERα in VSMCs from DPM compared with WT mice, although the difference was not statistically significant ( Figure 1D ). In this study, we further show that in VSMCs derived from WT mice, E2-treatment increases the binding between ERα and PP2Ac and increases PP2A activity in VSMCs derived from WT mice. These effects of estrogen were diminished or absent in VSMCs derived from DPM, supporting that estrogen enhances PP2A activity, possibly by increasing the interaction between ERα and PP2Ac, and that this is dependent on the rapid, non-nuclear pathway. In VSMCs derived from DPM, where ERα no longer binds to striatin, E2-induced ERα-PP2A complex formation was significantly attenuated, suggesting that striatin plays a critical role for ERα-PP2Ac complex formation mediated by E2. Furthermore, the inhibition of PP2A activity resulted in loss of the ability of estrogen to inhibit kinase phosphorylation and cell proliferation, suggesting that estrogen-induced antiproliferative effect on VSMCs is dependent on PP2A activation. Estrogen regulates physiology and pathophysiology in both reproductive and nonreproductive target tissues, including the cardiovascular system. 12 Estrogen exerts diverse actions in . siRNA oligo targeting PP2Ac or nontargeting control was introduced into VSMCs followed by E2 and platelet derived growth factor (PDGF) treatment as described in Figure 2 (n=4) . #P<0.05, *P<0.01. VSMCs derived from wild-type mice were treated with vehicle (V) or E2 in the presence or absence of okadaic acid (50 nmol/L), and cell proliferation was assessed in each condition cultured with 3% stripped bovine growth serum (sBGS) (B) and PDGF (5 ng/mL; C; n=4 per condition). #P<0.05 vs vehicle. these tissues in part because of the multiple signaling pathways mediated by ER, including both the canonical genomic pathway and the rapid, non-nuclear pathway. 12 The canonical genomic pathway of estrogen is itself quite diverse, as a result of differences in expression levels of ERs and ER-interacting proteins, which has produced the concept of tissue-specific selective ER modulators. 26, 27 Although the molecular mechanisms that mediate aspects of the rapid, non-nuclear pathway of estrogen have been studied in vascular endothelial cells, the role of the rapid signaling in VSMCs is poorly explored. 12 Although the current findings support that rapid ER signaling is necessary for estrogen-mediated inhibition of VSMC proliferation, they do not address whether rapid signaling by itself is sufficient to inhibit VSMC growth. Similarly, these findings do not rule out a role for genomic signaling in this effect because it remains possible that both rapid and genomic signaling pathways must be intact to allow for estrogen-mediated VSMC growth inhibition. The identification of rapid ER signaling as necessary for estrogen-mediated VSMC inhibition supports the possibility that pathway-selective ER modulators might be potentially promising candidates for specific therapies in CVDs, such as arthrosclerosis and restenosis, after percutaneous coronary interventions. Support for this concept has also recently been provided by the Shaul laboratory who demonstrated that administration of an estrogen dendrimer complex that selectively activates rapid ER signaling also inhibited the response to vascular injury in a mouse model. 28 Estrogen is known to accelerate proliferation of many cell types, which is clinically relevant to the effects of estrogen on tumors such as breast, ovary, and uterus. 29, 30 In these cancer cells, estrogen enhances the phosphorylation and activation of the same kinases that are inhibited in VSMCs in our study. Because this activation is crucial for the proproliferative effects of estrogen in these cells, if we can understand the molecular mechanisms that produce the opposite effect in VSMCs, we might be able to gain insight into how to block the proproliferative, cancer promoting effects of estrogen in these other cell types.
The evidence from randomized controlled trials suggests that treatment with estrogen early after menopause may be more effective in reducing the risk of CVDs than late treatment with estrogen. 6 However, although PP2A might play a role in the different effects of estrogen in early versus late, there is no direct evidence that the function of PP2A in the vasculature is altered after menopause. Further studies will be needed to address this specific point.
Several limitations of the current findings are worthy of mention. First, although the data presented support that E2, acting via ERα, activates PP2A catalytic activity, the molecular mechanisms that mediate this effect are unclear. Second, E2 has also been reported to interact with and regulate activity of phosphatases in addition to PP2A, such as MAPK kinase phosphatase-1 and phosphatase and tensin homolog, 25, 31, 32 and the extent to which effects on other phosphatases might also contribute to regulation of VSMC proliferation has not been tested here. Finally, although our data indicate that estrogen inhibits VSMC proliferation via PP2A activation through the rapid, non-nuclear pathway in cultured VSMCs, and the relevancy of the rapid pathway in vivo was observed in our previous study using DPM, 20 further in vivo studies are needed to assess whether PP2A activation by estrogen is also relevant in vivo.
In conclusion, our results support that the rapid, non-nuclear ER signaling is required for estrogen-induced inhibition of VSMC proliferation, and further that PP2A activation by estrogen mediates estrogen-induced antiproliferative effects in these cells. Taken together, our findings support that rapid, non-nuclear ER signaling may be a novel target for therapeutic approaches to inhibit VSMC proliferation, which plays a central role in vascular diseases such as atherosclerosis and restenosis. The proliferation of vascular smooth muscle cells plays a crucial role in vascular diseases, such as atherosclerosis and restenosis, after percutaneous coronary intervention. Although estrogen is known to inhibit vascular smooth muscle cell proliferation in response to vascular injury, the mechanisms that mediate these effects remain unclear. Here, we demonstrate that protein phosphatase 2A activation via noncanonical, rapid, non-nuclear estrogen receptor signaling is required for estrogen-induced inhibition of vascular smooth muscle cell proliferation by using a novel transgenic mouse line, in which rapid, non-nuclear estrogen receptor-mediated signaling is abolished. Our findings suggest that protein phosphatase 2A activation via the noncanonical estrogen receptor signaling may be a novel target for therapeutic approaches to inhibit vascular smooth muscle cell proliferation, which plays a central role in atherosclerosis and restenosis.
Significance
